| |
Explore how oncology developers are adapting to a highly competitive and uncertain oncology therapeutic landscape. .png)
|
|
Today’s Big NewsOct 28, 2024 |
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now. 
|
|
| By Nick Paul Taylor AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The buyout will give AbbVie control of an Alzheimer’s disease drug candidate that Aliada in-licensed from Johnson & Johnson to try to improve on the first generation of anti-amyloid-beta antibodies. |
|
|
|
By Fraiser Kansteiner EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this year. |
By Conor Hale Two late-breaking studies examined the early replacement of a patient's heart valve before they began showing symptoms of aortic stenosis, with mixed results. |
By Gabrielle Masson On the heels of a phase 3 win that failed to impress investors, Ironwood Pharmaceuticals is back with more data in efforts to prove that its long-acting GLP-2 analog can do more than beat placebo. |
|
Tuesday, November 12, 2024 | 2pm ET / 11am PT Major breakthroughs have been made recently in the research and development of Alzheimer’s disease. With a stronger understanding of disease pathology, new therapeutic pathways and the launch of the first disease-modifying treatments, join us to learn more about what the future holds in Alzheimer’s disease therapeutic development. Register now. 
|
|
By Fraiser Kansteiner Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor. |
By Darren Incorvaia The National Science Foundation has awarded $615,000 to the laboratory of chemist Doug Frantz, Ph.D., at the University of Texas at San Antonio (UTSA), for a partnership with BMS that seeks to make pharma manufacturing more environmentally friendly. |
By Kevin Dunleavy While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe. Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval of Izervay based on discussions with the European regulator. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
